Given the increased risk of cardiovascular events in the immediate postpartum period, postpartum care in an intensive care unit setting is recom­mended, and early discharge from the hospi­tal (<72 h) should be discouraged. Postpartum thromboprophylaxis should follow local pro­tocols. Postpartum monitoring of immunosup­pression levels and for infection is critical. In the general population, breastfeeding is associ­ated with a myriad of immunologic, emotional, and nutritional benefits. In HTx recipients, the decision to breastfeed should be based on a risk–benefit analysis of the potential for immu­nosuppressive medications to be excreted in the breast milk. After 1–2 weeks of breastfeeding, it is reasonable to check the infant’s serum for measurable drug levels of cyclosporine or tac­rolimus [78]. If significant levels are detected, the mother may be counseled to discontinue breastfeeding. Limited data are available regard­ing the excretion of mTOR inhibitors in breast milk. Therefore, caution must be advised regard­ing breastfeeding in mothers taking mTOR inhibitors. The Drugs and Lactation Database (LactMed) and e-lactancia can be helpful resources for physicians and patients when determining which medications are safe for breastfeeding mothers after HTx [79, 80].